» Articles » PMID: 11463512

Repeated Low-dose Treatment of Rats with Pilocarpine: Low Mortality but High Proportion of Rats Developing Epilepsy

Overview
Journal Epilepsy Res
Specialty Neurology
Date 2001 Jul 21
PMID 11463512
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic administration of pilocarpine in rats can result in a chronic behavioral state that is similar to human temporal lobe epilepsy. The pilocarpine model of epilepsy is widely used for studying the factors that contribute to the development of epilepsy as a consequence of status epilepticus (SE). For this purpose, pilocarpine is either administered alone at a high systemic dose or in combination with lithium, which markedly potentiates the convulsant effect of pilocarpine. Both experimental protocols, however, are associated with high mortality rates. In the present study, we evaluated whether mortality rate in rats can be decreased by repeated administration of low doses of pilocarpine. The time the rats spent in SE was limited by diazepam. Preliminary experiments in lithium-free rats indicated that repeated low-dose administration of pilocarpine is too time-consuming to produce SE compared to single high-dose administration. All subsequent experiments were performed in lithium-pretreated rats. Single-dose injection of 30 mg/kg pilocarpine produced SE in approximately 70% of the animals, but 45% of the rats died although SE was interrupted by diazepam after 90 min. Repeated i.p. administration of 10 mg/kg pilocarpine at 30-min intervals resulted in SE after 2-4 injections; the mean dose of pilocarpine needed to induce SE was 26 mg/kg. When SE was interrupted after 90 min, mortality rate was below 10%, which was significantly lower compared to the protocol with one single administration of 30 mg/kg pilocarpine. In contrast to mortality rate, the development of spontaneous recurrent seizures did not differ between experimental protocols. Almost all rats which had experienced a SE of at least 60 min developed chronic epilepsy. Average latency to the first spontaneous seizure was approximately 40 days. The frequency and severity of spontaneous seizures was not significantly different between protocols, although animal groups with repeated low-dose treatment tended to have higher frequencies of spontaneous seizures compared to single-dose administration. The present study demonstrates that systemic treatment of lithium-pretreated rats with several low doses of pilocarpine efficiently produces SE and chronic epilepsy with much lower mortality rates than single-dose pilocarpine.

Citing Articles

The Metabolic Profile of Plasma During Epileptogenesis in a Rat Model of Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy.

Antmen F, Matpan E, Dayanc E, Savas E, Eken Y, Acar D Mol Neurobiol. 2025; .

PMID: 39904962 DOI: 10.1007/s12035-025-04719-6.


Dose-Dependent Induction of Differential Seizure Phenotypes by Pilocarpine in Rats: Considerations for Translational Potential.

Vasovic D, Stanojlovic O, Hrncic D, Sutulovic N, Veskovic M, Ristic A Medicina (Kaunas). 2024; 60(10).

PMID: 39459366 PMC: 11509679. DOI: 10.3390/medicina60101579.


Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior.

Antmen F, Fedaioglu Z, Acar D, Sayar A, Yavuz I, Ada E Biomedicines. 2024; 12(10).

PMID: 39457518 PMC: 11505538. DOI: 10.3390/biomedicines12102205.


Wnt Signaling Modulators Exhibit Neuroprotective Effects via Combating Astrogliosis and Balancing Synaptic Density at Early and Late Stage Temporal Lobe Epilepsy.

Rawat K, Gautam V, Sandhu A, Kumar A, Sharma A, Bhatia A Neurochem Res. 2024; 49(11):3156-3175.

PMID: 39235578 DOI: 10.1007/s11064-024-04236-3.


A Novel Rat Infant Model of Medial Temporal Lobe Epilepsy Reveals New Insight into the Molecular Biology and Epileptogenesis in the Developing Brain.

Wormuth C, Papazoglou A, Henseler C, Ehninger D, Broich K, Haenisch B Neural Plast. 2024; 2024:9946769.

PMID: 39104708 PMC: 11300100. DOI: 10.1155/2024/9946769.